SciMatic Home SciMatic
  • Journals
  • Thesis Rep
  • Docs
  • Products
    SciMatic.net Journament Journal Manager Subjects Thesis ImProofer Research Groups Letter Pad Conferences
  • Services
  • About
    SciMatic Team Earn With Us Join Us Contact Us
Current Language EN
English English Türkçe Türkçe Español Español Português Português Pусский Pусский Filipino Filipino Tiếng Việt Tiếng Việt हिन्दी हिन्दी العربية العربية বাংলা বাংলা Deutsch Deutsch 中文 中文
Login

Keyword Connections

sulfonamides / adverse effects
Journals
0
No Journal Connected
Research Groups
0
No Research Group Connected
Bibliographies
4
1 Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosis
2 Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized Trials
3 Glecaprevir/pibrentasvir for hepatitis C virus genotype 3 patients with cirrhosis and/or prior treatment experience: A partially randomized phase 3 clinical trial
4 Efficacy of Glecaprevir/Pibrentasvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2, 4, 5, or 6 Infection Without Cirrhosis
About
  • About
  • Team
  • Join Us
  • Privacy and Security
  • Delete Account
  • Documentations
Services
  • Thesis Manager
  • Semester Manager
  • Journals
  • Conferences
  • Journament Indexings
  • API
Legal
SciMatic © 2014–2026

All Rights Reserved!

Creative Commons License
License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

SciBot
AI Assistant
Hi! I'm SciBot, your SciMatic assistant. I can help with manuscript submissions, journal info, and navigating the platform. How can I help?
Contact Us
Login Required

Register/Login first to send a message

Login